ERBB2 and neoplasm: Copanlisib (BAY 80-6946) and pictilisib (GDC-0941) induced tumor regression in a rat HER2-amplified PIK3CA-mutated and murine HER2 amplified PIK3CA-mutated breast cancer models, respectively [64, 65].